Surender Kharbanda

Chief Operating Officer
XYone Therapeutics Inc, United States

Disclosure information not submitted.

Presentation(s):

• Poster H6 - Characterizing Antitumor Activity of a Novel MUC1-C Targeting Antibody-Drug Conjugate for Treatment of Non-Small Cell Lung Cancer

  Thursday, October 24, 2024
  10:00 AM - 11:00 AM EST